This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Stavudine, d4T
Description: Zerit (Stavudine, d4T) is a synthetic thymidine nucleoside analogue with activity against the human immunodeficiency virus (HIV). Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate thymidine triphosphate and by causing DNA chain termination following its incorporation into viral DNA.
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Zerit for HIV. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.
Partners: DRI Capital Inc.
Additional information available to subscribers only: